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Crk was originally isolated as an oncogene product of the
CT10 chicken retrovirus. It belongs to a group of adaptor
proteins that are comprised of Src homology 2 (SH2) and
Src homology 3 (SH3) domains, which interact with
phosphotyrosine and proline-rich regions, respectively (Mayer
et al., 1988). The SH2 domain of Crk can bind to
phosphotyrosine-containing proteins such as the focal adhesion
components paxillin, p130 Crk-associate substrate (p130cas)
and growth factor receptors. The N-terminal SH3 domain of
Crk has been shown to bind to C3G (a guanine nucleotide
exchange factor/GEF for Rap1), Sos (GEF for Ras), DOCK180
(which activates Rac1 after binding to CrkII-p130cas
complexes), the protein tyrosine kinase c-Abl, protein tyrosine
phosphatase 1B (PTP1B), the phosphatidylinositol 3-kinase
p85 regulatory subunit and also c-Jun N-terminal kinase (JNK)
(Feller et al., 1998; Girardin and Yaniv, 2001). The C-terminal
SH3 domain of CrkII has been recently reported to interact
with the nuclear export receptor Crm1 (Smith et al., 2002).
CrkII has been implicated in integrin-mediated cell migration
by forming a complex with tyrosine-phosphorylated p130cas
(Klemke et al., 1998; Kain and Klemke, 2001). 
CrkII is known to be tyrosine phosphorylated after many
types of stimulation (Feller et al., 1998). Most of the total
population of CrkII molecules is tyrosine phosphorylated in
HeLa cells, but less than 40% of total CrkII is phosphorylated
on tyrosine 221 in various human cell lines (Hashimoto et al.,
1998). The tyrosine-phosphorylation site of CrkII is known to
serve as a high-affinity binding site for the SH2 domain of
CrkII, resulting in intramolecular binding of the SH2 domain to
phosphotyrosine 221 (Rosen et al., 1995). This intramolecular
binding results not only in a blockade of CrkII SH2-mediated
binding to phosphotyrosine residues in other molecules, but also
in reduced affinity for C3G due to masking or modification of
the CrkII central SH3 domain (Okada et al., 1998). 
Tyrosine phosphorylation of CrkII may induce negative
regulation. Substitution of tyrosine 221 to phenylalanine
greatly reduces the tyrosine phosphorylation of CrkII, yet it
increases the binding activity of CrkII to other phosphorylated
proteins (Escalante et al., 2000). Abl family tyrosine kinases
phosphorylate tyrosine 221 on CrkII, resulting in decreased
CrkII-to-p130cas association; Abl kinase also inhibits cell
migration (Kain and Klemke, 2001). CrkI, which is an
alternative spicing variant and lacks tyrosine 221 and the C-
terminal SH3 domain of CrkII, is upregulated and promotes
cell migration and invasion in glioblastoma (Takino et al.,
2003). However, it is not yet clear whether tyrosine-
phosphorylated CrkII is dephosphorylated by cellular
phosphatases, nor how crucial phosphorylation of CrkII at this
specific site is to the process of cell migration. 
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CrkII belongs to a family of adaptor proteins that become
tyrosine phosphorylated after various stimuli. We
examined the role of CrkII tyrosine phosphorylation in
fibronectin-induced cell migration. Overexpression of
CrkII inhibited dephosphorylation of focal adhesion
components such as p130 Crk-associated substrate
(p130cas) and paxillin by protein tyrosine phosphatase
1B (PTP1B). Tyrosine-phosphorylated CrkII was
dephosphorylated by PTP1B both in vitro and in vivo,
showing for the first time that PTP1B directly
dephosphorylates CrkII. A CrkII mutant in which tyrosine
residue 221 was substituted by phenylalanine (CrkII-
Y221F) could not be tyrosine phosphorylated, and it
showed significantly increased binding to p130cas and
paxillin. Enhanced binding of CrkII to p130cas has been
reported to promote cell migration. Nonphosphorylated
CrkII-Y221F promoted HT1080 cell migration on
fibronectin, whereas wild-type CrkII did not at moderate
expression levels. Moreover, co-expression of CrkII and
PTP1B promoted HT1080 cell migration on fibronectin and
retained tyrosine phosphorylation and binding of p130cas
to CrkII, whereas paxillin tyrosine phosphorylation was
reduced. These findings support the concepts that CrkII
binding activity is regulated by tyrosine kinases and
phosphatases, and that tyrosine phosphorylation of CrkII
can downmodulate cell migration mediated by the focal
adhesion kinase/p130cas pathway.
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In the present study, we examined whether PTP1B could
dephosphorylate CrkII. PTP1B was able to directly
dephosphorylate CrkII, as well as its SH2 binding proteins
p130cas and paxillin. A CrkII mutant with tyrosine residue 221
substituted by phenylalanine (CrkII-Y221F) could not be
tyrosine phosphorylated, and it showed significantly increased
binding to p130cas and paxillin. The CrkII-Y221F mutant, but
not wild-type CrkII, promoted cell migration on fibronectin
concomitant with increased binding to p130cas and its SH3-
binding proteins. This CrkII-Y221F-induced cell migration
was suppressed by co-transfecting with dominant-negative
(DN) Rac1 but not wild-type Rac1. Moreover, co-expression
of CrkII and PTP1B promoted HT1080 cell migration on
fibronectin, whereas expression of either regulatory protein
alone did not. These findings provide evidence that the
regulation of CrkII activity by tyrosine phosphatase/kinase
targeting of tyrosine 221 is an important factor in cell migration




Green fluorescent protein (GFP) expression plasmids based on
pGZ21 d xZ that contained no insert, full-length wild-type chicken
PTP1B or dominant-negative p130cas (psSRa -DN-p130cas) were
constructed as described previously (Tamura et al., 1999a; Tamura et
al., 1999b). The pRK-VSV-CrkII (where VSV is vesicular stomatitis
virus epitope) and pcDNA-CrkII expression plasmids were generated
by transferring the CrkII cDNA insert from pCEFL-GST-CrkII to
pRK-VSV and pcDNA3 after BamHI and NotI digestion. The CrkII
SH2 mutant (CrkII-R38L), the CrkII N-terminal SH3 mutant (CrkII-
W169L) and CrkII-Y221F were generated by substitutions of arginine
38 to leucine, tryptophan 169 to leucine, and tyrosine 221 to
phenylalanine using the QuikChange™ site-directed mutagenesis kit
(Stratagene), respectively, and then they were transferred to pcDNA3
(Invitrogen) expression vectors. Catalytically inactive PTP1B
(PTP1B-C215S) was constructed by substitution of cysteine 215
within the consensus PTP catalytic domain to serine. The pHA262pur
puromycin-resistance plasmid was kindly provided by Hein te Riele
(Netherlands Cancer Institute, Amsterdam, The Netherlands).
Antibodies and reagents 
Mouse monoclonal anti-phosphotyrosine (PY20), anti-p130cas, anti-
Crk, anti-FAK (focal adhesion kinase), and anti-paxillin antibodies
were purchased from Transduction Laboratories. Rabbit polyclonal
anti-p130cas (C-20), anti-CrkII and anti-GFP antibodies were from
Santa Cruz Biotechnology. Mouse monoclonal anti- a -tubulin, anti-
VSV glycoprotein and anti-GST antibodies, and Dulbecco’s modified
Eagle’s medium (DMEM) were from Sigma-Aldrich. Mouse
monoclonal anti-PTP1B antibody was from Calbiochem. Cy3-
conjugated mouse immunoglobulin G from Jackson ImmunoResearch
Laboratories and rhodamine-labeled phalloidin from Molecular
Probes were used at 1:1000 dilution. Recombinant human PTP1B was
from Upstate Biotechnology. 
Cell culture and transfection
The human embryo kidney 293-EBNA cell line was purchased from
Invitrogen. HT1080 cells were obtained from ATCC. Cells were
maintained in DMEM supplemented with 5% fetal bovine serum, 100
units/ml penicillin and 100 m g/ml streptomycin and cultured in 5%
CO2 at 37° C. HT1080 cells were seeded at 5 · 104 cells/ml and 293-
EBNA cells at 1· 105 cells/ml at 24 hours before transfection.
Transient transfections were performed by standard calcium
phosphate methods.
Silencing of endogenous PTP1B with small interfering RNA
(siRNA)
Purified, duplexed siRNA for PTP1B and b -actin were purchased
from Dharmacon. The siRNA sequence targeting human PTP1B
(GenBank accession number M31724) was from position 799-819.
Twenty microlitres of siRNA (20 m M) plus 1 m g of pcDNA3 and 1
m g of pRK-GFP plasmids were transfected into 293-EBNA cells
cultured in 60 mm diameter dishes by calcium phosphate co-
precipitation. At 36 hours after transfection, the cells were trypsinized,
suspended in DMEM containing 1 mg/ml bovine serum albumin
(BSA) for 20 minutes, and replated on fibronectin-coated dishes for
the indicated periods.
Immunoprecipitation and immunoblotting 
Cells were washed twice with ice-cold phosphate-buffered saline
(PBS) and homogenized in a buffer containing 50 mM Tris-HCl (pH
7.5), 150 mM NaCl, 1 mM EGTA, 1 mM PMSF, 1 mM Na3VO4, 1
mM NaF, 1% NP-40, 0.25% sodium deoxycholate and protease
inhibitor cocktail (Boehringer Mannheim, Germany). Cell lysates
were centrifuged at 15,000 g for 15 minutes at 4 ° C to remove
insoluble material. Protein concentrations of lysates were determined
using a bicinchoninic acid protein assay kit (Pierce) and samples were
adjusted to equal protein concentration and volume. The samples were
used for immunoprecipitation with the indicated antibodies for
2 hours at 4 ° C followed by sedimentation with GammaBind
Plus Sepharose™ (Amersham Pharmacia Biotech). The
immunoprecipitates were separated by sodium dodecyl sulphate-
polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to
nitrocellulose membranes. The membranes were blocked with 3%
BSA in TBS-T (50 mM Tris-HCl, 150 mM NaCl, 0.1% Tween-20)
for 1 hour at room temperature (RT), then probed with the indicated
antibodies for 2 hours at RT. After washing the membranes in three
10 minute washes with TBS-T, the membranes were incubated with
horseradish peroxidase-linked secondary antibody (Amersham
Pharmacia Biotech) for 1 hour at RT followed by enhanced
chemiluminescence detection using SuperSignal™ (Pierce). The
membranes were then stripped with 2% SDS, 100 mM b -
mercaptoethanol in 62.5 mM Tris-HCl, pH 6.8, for 20 minutes at
70° C. Stripped membranes were washed extensively in TBS and
placed in 3% BSA blocking buffer overnight, and then were re-probed
with another antibody as indicated.
Protein phosphatase assay
PTP1B dephosphorylation of CrkII was examined using an in-blot
phosphatase assay. In brief, phosphorylated CrkII and FAK were
obtained from immunoprecipitates with anti-VSV antibody from
lysates of 293-EBNA cells co-transfected with VSV-FAK and VSV-
CrkII. Immunoprecipitated FAK and CrkII were subjected to SDS-
PAGE and transferred to nitrocellulose membranes. The membrane
was incubated with 20 U/ml recombinant PTP1B in assay buffer
containing 25 mM HEPES (pH 7.2), 50 mM NaCl, 2.5 mM EDTA,
and 5 mM dithiothreitol (DTT) at 37 ° C for 30 minutes. The
phosphorylation state of FAK and CrkII was determined with anti-
phosphotyrosine antibody (PY20). The membrane was then re-probed
with anti-VSV antibody.
Cell motility
HT1080 cells were co-transfected with 2 m g pcDNA-CrkII-WT,
pcDNA-CrkII-W169L or pSSRa -DN-p130cas, or either 0.5 m g
pcDNA-CrkII-WT or pcDNA-CrkII-Y221F together with 0.5 m g GFP
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(pGZ21d xZ) and pHA262pur puromycin-resistance plasmids. The
cells were subcultured at a 1:3 dilution 12 hours after transfection and
maintained for 36 hours in 1.5 m g/ml puromycin-containing medium.
This selection for transient transfectants routinely resulted in 90%
positive cells expressing GFP as determined by fluorescence
microscopy. After puromycin selection, cells expressing various
constructs were washed twice with DMEM containing 1 mg/ml BSA
and replated on 35 mm glass-bottom microwell dishes (MatTek)
coated with 10 m g/ml fibronectin; the cells were cultured overnight in
the same serum-free medium. Cell movements were monitored using
Zeiss inverted microscopes. Video images were collected with
Newvicon cameras (model 2400; Hamamatsu Photonics) at 20 minute
intervals, digitized and stored as image stacks using MetaMorph 3.5
software (Universal Imaging). Image stacks were converted to
QuickTime movies, and the positions of nuclei were tracked to
quantify cell motility using Move-tr/2D software (Library, Tokyo,
Japan). 
Alternatively, migration assays were performed in 48-well
chemotaxis chambers (Neuro Probe). Cells selected by puromycin
were trypsinized, kept in suspension for 20 minutes to recover from
the trypsinization, then added to the upper wells of chambers
separated from the lower wells by a polycarbonate membrane coated
with 10 m g/ml fibronectin. Cells were allowed to migrate for 10 hours
at 37° C. The membrane was fixed, stained and scanned before and
after wiping the upper side to remove non-migrating cells. 
Immunofluorescence staining 
Glass coverslips (12 mm diameter) were coated with 10 m g/ml
fibronectin in PBS overnight at 4 ° C, and then blocked with 5 mg/ml
BSA for an additional 1 hour at 37 ° C. After puromycin selection, cells
expressing GFP-PTP1B were washed twice with DMEM containing
1 mg/ml BSA and replated on the coverslips, and were then cultured
for 2 hours in DMEM containing 1 mg/ml BSA. The cells were fixed
with 4% paraformaldehyde in PBS for 20 minutes, then were
permeabilized with 0.5% Triton X-100 and 4% paraformaldehyde in
PBS for 5 minutes. Focal adhesions were visualized by incubating
first with mouse anti-paxillin monoclonal antibody for 1 hour at RT,
then with Cy3-conjugated goat antibody to mouse immunoglobulin
G. Actin filaments were stained with rhodamine-labeled phalloidin.
Localization was evaluated by confocal laser microscopy (Carl Zeiss,
LSM510).
Results
CrkII protects p130cas from dephosphorylation
We first analyzed the effects of CrkII expression on the levels
of tyrosine phosphorylation of the focal adhesion components
FAK, paxillin and p130cas. As shown in Fig. 1A,
overexpression of CrkII (2 m g) by transfection moderately
enhanced the tyrosine phosphorylation of p130cas, and it
Fig. 1. CrkII protects p130cas from dephosphorylation. (A) 293-
EBNA cells were transfected with either pRK-VSV-CrkII (2 m g) or
pRK-GFP-PTP1B (2 m g) expression plasmids, or co-transfected
with pRK-VSV-CrkII and pRK-GFP-PTP1B. Cell lysates were
immunoprecipitated with anti-p130cas (IP: p130cas), anti-paxillin
(IP: paxillin) or anti-FAK (IP: FAK) antibodies, and then
immunoblotted with anti-phosphotyrosine (Blot: pTyr), anti-p130cas
(Blot: p130cas), anti-paxillin (Blot: paxillin) or anti-FAK (Blot:
FAK) antibodies. The whole-cell lysates (WCL) were
immunoblotted with anti-GFP (Blot: GFP) or anti-VSV (Blot: VSV)
antibodies. The numerical values indicate relative ratios as a
percentage of the control for each band of phosphoprotein/total
protein after scanning and analysis using NIH Image software.
(B) pRK-GFP-PTP1B (2 m g) and various quantities of pcDNA-CrkII
expression plasmids as indicated were co-transfected in 293-EBNA
cells. Cell lysates were immunoprecipitated with anti-p130cas (IP:
p130cas) and then immunoblotted with anti-phosphotyrosine (Blot:
pTyr), anti-p130cas (Blot: p130cas) or anti-Crk (Blot: Crk)
antibodies. The whole-cell lysates (WCL) were immunoblotted with
anti-GFP (Blot: GFP) or anti-Crk (Blot: Crk) antibodies. The
numbers indicate relative ratios as a percentage of controls for
phosphoprotein/total protein or for CrkII bound to p130cas compared
with the control.
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slightly elevated the phosphorylation of paxillin without
affecting that of FAK. CrkII was previously shown to bind
preferentially to phosphotyrosine on the epidermal growth
factor receptor and p130cas, and CrkII binding protects these
phosphotyrosine sites from cellular phosphatase activities
(Birge et al., 1992). From other studies, it was known that
PTP1B can dephosphorylate p130cas and paxillin (Liu et al.,
1996). Consequently, we investigated whether CrkII could
protect p130cas and paxillin from
dephosphorylation by PTP1B.
Expression by transfection of
GFP-PTP1B (2 m g) markedly
reduced the tyrosine
phosphorylation of p130cas and
paxillin, while phosphorylation
levels of FAK were not altered
(Fig. 1A). Total protein levels of
all three proteins remained
unchanged. Co-expression of
CrkII with GFP-PTP1B using
equal plasmid concentrations
completely restored the
phosphorylation levels of p130cas
and slightly enhanced those of
paxillin, without affecting FAK
phosphorylation (Fig. 1A). 
To determine which domain of
CrkII is responsible for protecting
p130cas from dephosphorylation
by PTP1B, 293-EBNA cells were
co-transfected with GFP-PTP1B
and mutants of CrkII. As shown in
Fig. 1B, only the CrkII SH2
mutant (CrkII-R38L) failed to protect and bind to tyrosine-
phosphorylated p130cas, whereas two other mutants including
Y221F (mutation of tyrosine 221 to phenylalanine) bound
similarly or better than wild-type. Thus, although GFP-PTP1B
can effectively induce p130cas dephosphorylation, co-
expression of CrkII restores tyrosine phosphorylation of
p130cas by binding to p130cas through its SH2 domain. These
results indicate that CrkII binding to p130cas can protect its
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Fig. 2. PTP1B directly
dephosphorylates CrkII. (A) An in-
blot tyrosine phosphatase assay was
performed as described in Materials
and Methods. Immunoprecipitates
using anti-VSV antibody (IP: VSV)
from lysates of 293-EBNA cells co-
transfected with VSV-FAK and VSV-
CrkII were subjected to SDS-PAGE
and electroblotting. The membranes
were incubated with recombinant
human PTP1B (20 U/ml) at 37 ° C for
30 minutes, then immunoblotted with
anti-phosphotyrosine (Blot: pTyr) or
anti-VSV antibodies (Blot: VSV).
(B) 293-EBNA cells were co-transfected with either 0.5 m g of pcDNA CrkII-WT or CrkII-
Y221F with or without pRK-GFP-PTP1B (2 m g), and then homogenized in NP-40 buffer.
The cell lysates were immunoprecipitated with anti-Crk (IP: Crk) polyclonal antibody, and
then immunoblotted with anti-phosphotyrosine (Blot: pTyr) or anti-Crk (Blot: Crk)
monoclonal antibodies. The whole-cell lysates (WCL) were immunoblotted with anti-GFP
antibody (Blot: GFP). (C) Immunoprecipitates using anti-CrkII antibody (IP: CrkII) from
lysates of 293-EBNA cells co-transfected with pcDNA-CrkII and either pRK-GFP-PTP1B
or GFP-PTP1B-C215S were subjected to SDS-PAGE and immunoblotting with anti-
phosphotyrosine (Blot: pTyr) or anti-CrkII (Blot: CrkII) antibodies. The whole-cell lysates
were immunoblotted with anti-GFP-antibody (Blot: GFP). (D) 293-EBNA cells co-
transfected with either pcDNA-CrkII-WT or CrkII-Y221F were homogenized, and the
lysates were immunoprecipitated with either anti-p130cas (IP: p130cas) or anti-paxillin
(IP: paxillin) antibodies, and then immunoblotted with anti-Crk (Blot: Crk), anti-p130cas
(Blot: p130cas), or anti-paxillin (Blot: paxillin) antibodies. 
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phosphotyrosine from PTP1B; paxillin was less effectively
protected. 
PTP1B dephosphorylates CrkII
We tested the hypothesis that PTP1B can directly
dephosphorylate CrkII using an in-blot phosphatase assay.
Incubation with recombinant human PTP1B significantly
reduced the tyrosine phosphorylation of CrkII compared
with controls (Fig. 2A). By contrast, PTP1B did not
dephosphorylate FAK, indicating that PTP1B can directly and
specifically dephosphorylate CrkII in vitro. To determine
whether expression of PTP1B could also reduce the tyrosine-
phosphorylation level of CrkII in vivo, either 0.5 m g of CrkII-
WT or CrkII-Y221F was co-expressed in 293-EBNA cells with
or without 2 m g of GFP-PTP1B, and both CrkII tyrosine
phosphorylation and the tyrosine-phosphorylated proteins co-
precipitating with CrkII were analyzed (Fig. 2B). Although
overexpressed CrkII-WT was tyrosine phosphorylated,
co-expression with GFP-PTP1B abrogated tyrosine
phosphorylation of CrkII. In parallel with the loss of
phosphorylated CrkII, the electrophoretic mobility of CrkII-
WT in cells co-expressing GFP-PTP1B shifted to a single band
with faster migration, due to loss of the more-slowly migrating
band of a doublet; this result is consistent with
dephosphorylation. CrkII-Y221F migrated with slightly higher
mobility, and it did not stain with anti-phosphotyrosine
antibody; it remained as a single band regardless of GFP-
PTP1B co-expression. Thus, PTP1B could dephosphorylate
CrkII and shift its mobility, unless CrkII was mutated at Y221. 
Overexpression of the catalytically inactive mutant of PTP1B
(PTP1B-C215S) had no effect on CrkII phosphorylation (Fig.
2C), further supporting a role for PTP1B as a phosphatase
for CrkII in vivo. Tyrosine-phosphorylated proteins of
approximately 130 kDa and 67 kDa (same sizes as p130cas and
paxillin) were found to co-precipitate substantially more with
CrkII-Y221F than with CrkII-WT (Fig. 2B). The identity of
these proteins co-precipitating with CrkII-Y221F was confirmed
by immunoprecipitation using anti-p130cas and anti-paxillin
antibodies. As shown in Fig. 2D, CrkII-Y221F was considerably
more effectively co-precipitated with both p130cas and paxillin
compared with CrkII-WT. These data suggest a negative role for
Y221 phosphorylation in these CrkII interactions.
Fibronectin promotes partial CrkII dephosphorylation
Although the adhesion of cells to fibronectin is associated with
well-known increases in tyrosine phosphorylation, including
phosphorylation of FAK and
p130cas, our findings with the
CrkII-Y221F mutant suggested
that there might actually be
a concomitant loss of
phosphorylation of CrkII. As
shown in Fig. 3AB, attachment
of 293-EBNA and HT1080 cells
to fibronectin induced tyrosine
phosphorylation and binding of
p130cas to CrkII compared with
detached cells in suspension.
Concomitantly, however, CrkII
Fig. 3. Fibronectin promotes
dephosphorylation of CrkII.
(A) 293-EBNA and HT1080 cells
were serum-starved for 6 hours or
12 hours, respectively. The cells were trypsinized, kept in suspension for 20 minutes,
re-plated onto culture dishes coated with 10 m g/ml fibronectin for 10, 30 or 120
minutes, and then homogenized. The 293-EBNA lysates were immunoprecipitated with
anti-p130cas (IP: p130cas) or anti-Crk (IP: Crk) antibodies, and then immunoblotted
with anti-phosphotyrosine (Blot: pTyr), anti-p130cas (Blot: p130cas) or anti-Crk (Blot:
Crk) antibodies. The whole-cell lysates (WCL) from HT1080 cells were immunoblotted
with anti-Crk (Blot: Crk) antibody. (B) HT1080 cells were serum-starved for 12 hours,
trypsinized, kept in suspension for 20 minutes, then replated onto culture dishes coated
with 10 m g/ml fibronectin for 30 or 120 minutes. The cells were homogenized and
immunoprecipitated with anti-p130cas (IP: p130cas) or anti-Crk (IP: Crk) antibodies,
and then immunoblotted with anti-phosphotyrosine (Blot: pTyr), anti-p130cas (Blot:
p130cas) or anti-Crk (Blot: Crk) antibodies. (C) HT1080 cells in 100 mm dishes were
co-transfected with 1 m g of pHA262pur and 2 m g of pRK-GFP-PTP1B, and
transfectants were selected by puromycin for 36 hours. After puromycin selection, cells
were serum-starved for 12 hours and replated onto culture dishes coated with 10 m g/ml
fibronectin for 2 hours. The cells were homogenized and immunoprecipitated with anti-
p130cas (IP: p130cas) antibody, and then immunoblotted with anti-phosphotyrosine
(Blot: pTyr) or anti-p130cas (Blot: p130cas) antibodies. The whole-cell lysates (WCL)
were immunoblotted with anti-PTP1B (Blot: PTP1B) or anti-Crk (Blot: Crk)
antibodies. 
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was dephosphorylated as indicated by western
immunoblotting. This loss of phosphorylation was
accompanied by an electrophoretic mobility shift of CrkII,
which formed a doublet band with a faster-migrating
component lacking tyrosine phosphorylation (Fig. 3A,B,C). In
HT1080 cells transfected with PTP1B, this fibronectin-induced
mobility shift involved nearly all CrkII molecules (as indicated
by the loss of nearly the entire upper band of the doublet), and
the tyrosine phosphorylation of p130cas induced by fibronectin
stimulation was reduced (Fig. 3C).
PTP1B is essential for fibronectin-induced CrkII
dephosphorylation
Our results showing that dephosphorylation of CrkII is induced
by PTP1B expression and fibronectin stimulation suggests
that PTP1B may be involved in fibronectin-promoted
dephosphorylation of CrkII. To test the ability of PTP1B to
dephosphorylate CrkII with fibronectin stimulation, we used a
short interfering dsRNA (siRNA) RNA interference approach
to achieve knockdown of endogeneous PTP1B levels. PTP1B
was downregulated in the cells transfected with siRNA for
PTP1B but not with actin siRNA (Fig. 4A). By contrast, actin
was decreased in the cells transfected with siRNA for actin but
with PTP1B siRNA, confirming specific downregulation of
PTP1B by siRNA transfection. As shown in Fig. 4B,
attachment of 293-EBNA cells to fibronectin induced
dephosphorylation of CrkII compared with detached cells in
suspension, which was consistent with the previous results in
Fig. 3. Concomitant with the decreased levels of PTP1B, the
faster-migrating component (dephosphorylated CrkII) was
decreased in PTP1B siRNA knockdown cells compared with
control cells, both when cells were kept in suspension and
when plated onto fibronectin (Fig. 4B).
Subcellular localization of PTP1B
PTP1B contains two proline-rich domains, which are
consensus sequences for SH3 domain-binding motifs, and it
selectively binds to the SH3 domains of Grb2, Crk and p130cas
(Liu et al., 1996). We next investigated the subcellular
distribution of PTP1B and CrkII in cells stimulated with
fibronectin. HT1080 cells transfected with GFP-PTP1B were
plated on fibronectin-coated coverslips and analyzed by
confocal immunofluorescence microscopy. As shown in Fig. 5,
CrkII was mainly distributed in the cytoplasm with some
membrane-associated staining. Consistent with a previous
study, PTP1B was not only strongly localized to the
endoplasmic reticulum, but also extended to the cell periphery.
This pattern of PTP1B localization was at times parallel to
microtubules, and it ended at focal adhesions. Co-localization
between CrkII and PTP1B was observed faintly at plasma
membrane-associated sites (Fig. 5). 
Effects of CrkII phosphorylation on cell migration
The association of CrkII with p130cas has been shown by
Klemke et al. (Klemke et al., 1998) to regulate FG pancreatic
carcinoma cell migration on fibronectin. HT1080 cells were
transfected with high or low amounts of plasmids encoding
CrkII-WT or CrkII-Y221F, and the dominant-negative p130cas
(p130casDSD) and the central SH3 mutant of CrkII (CrkII-
SH3M) were tested for effects on rates of cell migration on
fibronectin. Both p130casDSD and CrkII-SH3M reduced cell
migration to 60% of control cells (P<0.001). High but not low
levels of CrkII-WT overexpression enhanced HT1080 cell
migration by 35% compared with control cells (P<0.001). By
contrast, low but not high levels of nonphosphorylated CrkII-
Y221F expression significantly increased the average rate of
cell migration 47% above controls (Fig. 6A; P<0.001). Fig. 6B
shows the morphology of the transfected cells at 12 hours after
replating onto fibronectin. Concomitant with the increase of
migration, the cells expressing high levels of CrkII-WT (high)
and low levels of CrkII-Y221F (low) shows pseudopodial
extension and membrane ruffling compared with control and
low-level expressors of CrkII-WT (low). By contrast, high
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Fig. 4. PTP1B is essential for effective fibronectin-induced CrkII
dephosphorylation. (A) 293-EBNA cells were co-transfected with
siRNA (2· 10–11 or 2 · 10–10 mol) for either PTP1B or b -actin and
pRK-GFP and pcDNA3 plasmids. The cells were homogenized at 36
hours after transfection and immunoblotted with anti-PTP1B (Blot:
PTP1B) or anti-actin (Blot: actin) antibodies. (B) 293-EBNA cells
were co-transfected with siRNA for PTP1B, and pRK-GFP and
pcDNA3 plasmids. At 36 hours after transfection, cells were
trypsinized, kept in suspension for 20 minutes, and replated onto
culture dishes coated with 10 m g/ml fibronectin for 30 or 120
minutes. The cells were homogenized and immunoblotted with anti-
PTP1B (Blot: PTP1B), anti-Crk (Blot: Crk) or anti-GFP (Blot: GFP)
antibodies.
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levels of CrkII-Y221F expression were accompanied by
random pseudopodial extension and a flattened, more-spread
morphology consistent with increased cell-substrate adhesion.
Co-expression of CrkII and PTP1B promotes cell
migration
Although our mutational analysis of CrkII at residue Y221
strongly suggested that lack of phosphorylation of this
site mimicking fibronectin-induced reduction of CrkII
phosphorylation can regulate migration, the direct
experimental test would be to induce CrkII dephosphorylation
by PTP1B and to examine its effects on cell migration. HT1080
cells were co-transfected with CrkII and various concentrations
of the GFP-PTP1B expression plasmid. After 36 hours of
puromycin selection, the cells were serum-starved for 12 hours
and replated onto culture dishes coated with fibronectin for 2
hours; tyrosine phosphorylation of p130cas and paxillin were
analyzed by immunoprecipitation and immunoblotting. As
shown in Fig. 7A, the co-expression of PTP1B with CrkII
significantly decreased the binding of CrkII to paxillin, but not
its binding to p130cas. Although the tyrosine phosphorylation
of paxillin was attenuated by PTP1B regardless of co-
expression with CrkII, tyrosine phosphorylation of p130cas
was protected by CrkII expression, suggesting that CrkII
dephosphorylated by PTP1B preferentially bound to and
protected tyrosine-phosphorylated p130cas, but
not paxillin. As shown in Fig. 7B, HT1080 cell
migration rates on fibronectin were increased
in the cells co-expressed with CrkII and
PTP1B, and CrkII-Y221F with or without
PTP1B (to 119%, 125% and 121% of controls,
respectively; P<0.05), but not in the cells
expressed CrkII or PTP1B alone. These results
indicate that CrkII dephosphorylated by
PTP1B preferentially binds to and protects
tyrosine-phosphorylated p130cas (but not
paxillin) associated with promotion of cell
migration.
Discussion
In this study we have established the following
novel points: first, PTP1B directly
dephosphorylates CrkII in vitro and in vivo;
second, CrkII is tyrosine-phosphorylated in
cells in suspension, and it is dephosphorylated
by attachment to fibronectin and PTP1B
expression; third, nonphosphorylated CrkII-
Y221F can increase HT1080 cell migration on
fibronectin, whereas wild-type CrkII cannot at
moderate expression levels; and fourth, CrkII
dephosphorylated by PTP1B preferentially
binds to and protects tyrosine-phosphorylated
p130cas, but not paxillin, in association with
accelerated cell migration. 
The CrkII adaptor protein has been
implicated in signal transduction cascades by
its association with SH2- and SH3-binding
partner proteins. Tyrosine dephosphorylation
of p130cas was effectively prevented by binding
of CrkII (Fig. 1 of this study). CrkII itself is
phosphorylated at residue tyrosine 221 after
many types of stimuli (Matsuda and Kurata,
1996). Abl tyrosine kinase, which binds to the
N-terminal SH3 domain of CrkII, is a negative
regulator of cell migration through its ability
to regulate the p130cas/CrkII complex
accompanied by phosphorylation of the
tyrosine 221 residue of CrkII, suggesting the
importance of CrkII tyrosine phosphorylation
in cell migration (Kain and Klemke, 2001). By
mutational analysis, we show in this study that
tyrosine 221 can be directly linked to the rate
Fig. 5. Subcellular localization of PTP1B and CrkII. HT1080 cells in 60 mm dishes
were co-transfected with 0.5 m g of pHA262pur and 1 m g of pRK-GFP-PTP1B, and
transfectants were selected by puromycin for 36 hours. After puromycin selection,
cells were replated on glass coverslips coated with 10 m g/ml fibronectin for 2 hours.
The cells were analyzed by immunofluorescence confocal microscopy using anti-Crk
(Crk), anti-paxillin (Paxillin), or anti-b -tubulin (Tubulin) antibodies, or rhodamine-
phalloidin (F-actin). Bars, 20 m m.
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of cell migration (Figs 6, 7). The mechanism by which CrkII
might be dephosphorylated and its binding activated has not
been clear. Here, we provide, to the best of our knowledge, the
first evidence that PTP1B can directly dephosphorylate CrkII
both in vitro and in intact cells (Figs 2-4). 
PTP1B is a ubiquitous endoplasmic reticulum-associated
enzyme, which is also localized at focal adhesions (Frangioni
et al., 1992; Arregui et al., 1998). We also found that PTP1B
was mainly localized at the endoplasmic reticulum, but also
extended to the cell periphery. This peripheral population was
parallel to some microtubules, ended at focal adhesions, and
was accompanied by faint co-localization between CrkII and
PTP1B when the cells were plated onto fibronectin (Fig. 5).
PTP1B has been implicated in the negative regulation of cell
growth, differentiation and transformation (Byon et al., 1997).
Liu et al. (Liu et al., 1998) reported that overexpression of
PTP1B in Rat-1 fibroblasts resulted in markedly reduced
migration on fibronectin. By contrast, several lines of evidence
suggest an opposite role for PTP1B in integrin-mediated
signaling. Expression of a catalytically inactive mutant of
PTP1B in L cells decreases fibronectin-mediated cell spreading
and FAK phosphorylation, whereas wild-type PTP1B had no
effect (Arregui et al., 1998). We also could not show any
negative effect of overexpressing PTP1B alone on fibronectin-
induced cell migration and spreading in two other cell types,
U87-MG and HT1080 cells (Tamura et al., 1998) (Fig. 7B).
Furthermore, overexpression of PTP1B in breast cancer
cells (MDA-MB-435S) and HEK293 cells decreases
phosphorylation of the c-Src inhibitory site (Tyr-527), resulting
in an increase in Src kinase activity, which is essential for
adhesion-dependent p130cas phosphorylation (Bjorge et al.,
2000). It is likely, therefore, that the different phenotypes
resulting from PTP1B expression may be due to differences in
cell types and/or expression levels of PTP1B. Interestingly,
embryonic fibroblasts from PTP1B knockout mice display
significant delays in p130cas phosphorylation and cell
spreading induced by attachment to fibronectin (Cheng et al.,
2001). Our findings that CrkII phosphorylation is reduced
by fibronectin stimulation and further reduced by PTP1B
expression, and that 293-EBNA cells with PTP1B knockdown
by siRNA show decreased CrkII dephosphorylation induced by
attachment to fibronectin suggest a positive role of PTP1B in
integrin-mediated signaling (Figs 3, 4). Indeed, Src Tyr-527 is
hyperphosphorylated in PTP1B-deficient fibroblasts compared
with wild-type, but only when the cells are held in suspension
and not when plated onto fibronectin (Cheng et al., 2001). We
found that detachment of cells (cells maintained in suspension)
can induce CrkII phosphorylation, which is also elevated in
PTP1B knockdown cells and is reduced by PTP1B expression
(Figs 3, 4). These data suggest that the high levels of
phosphorylation of CrkII in cells kept in suspension may result
in the attenuation of fibronectin-mediated events. However,
PTP1B knockdown did not increase cell migration (data not
shown), implying the involvement of other phosphatases or
small remnants of PTP1B in dephosphorylation of CrkII. In
fact, a recent study has reported that even though PTP1B–/–
cells can exhibit enhanced tyrosine phosphorylation of
epidermal growth factor (EGF) receptor or platelet-derived
growth factor (PDGF) receptor in response to EGF or PDGF
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Fig. 6. CrkII-Y221F accelerates cell motility on fibronectin.
(A) HT1080 cells were co-transfected with 0.5 m g of pHA262pur,
0.5 m g of pRK-GFP, and 0.5 m g or 2 m g of pcDNA-CrkII-WT and
pcDNA-CrkII-Y221F, or 2 m g of CrkII-W169L, psSR a -DN-p130cas
or control plasmids, and transfectants were selected by puromycin
for 36 hours. After puromycin selection,
cells were replated on 35 mm glass
dishes coated with 10 m g/ml fibronectin,
and cultured overnight in serum-free
DMEM containing 1 mg/ml BSA. Cell
movements were monitored for 3 hours
by time-lapse video microscopy. Error
bars indicate s.d. for at least 30 cells per
condition (*P<0.001 versus controls).
Parallel cultures of these cells were
homogenized and subjected to
immunoblotting with anti-Crk (WCL
Blot: Crk) antibody. (B) Phase contrast
microscopy of HT1080 cells co-
transfected with 0.5 m g of pHA262pur,
pRK-GFP, and 0.5 m g (low) or 2 m g
(high) of pcDNA-CrkII-WT, CrkII-
Y221F or control plasmids 12 hours after
replating onto fibronectin. Magnification,
· 200.
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stimulation, Akt and ERK activation are only minimally or not
enhanced (Haj et al., 2003). The authors suggest that even
though PTP1B plays a role in regulating EGFR and PDGFR,
other regulatory mechanisms come into play when it is
missing; they speculate that this finding might explain why no
classical protein tyrosine phosphatases have been found to be
tumor suppressor genes. PTP1B might be important in cell
migration by activating CrkII and Src in a process dependent
on their relative intracellular concentrations.
CrkII has been identified as a mediator of cell migration
through its association with p130cas and paxillin (Klemke et al.,
1998). The p130cas/CrkII/DOCK180 pathway is reported to
promote cell migration and to activate Rac1 (Kiyokawa et al.,
1998a; Kiyokawa et al., 1998b). As documented in Fig. 2,
CrkII-Y221F can bind more effectively to paxillin and p130cas
than wild-type CrkII, suggesting that the expression of CrkII-
Y221F might facilitate this pathway. At a relatively low
expression level where wild-type CrkII could not stimulate cell
migration, nonphosphorylated CrkII-Y221F could readily
promote HT1080 cell migration on fibronectin. By contrast,
high expression of CrkII-Y221F did not elevate rates of cell
migration in these cells, which displayed enhanced random
pseudopodial extension and a flattened, more-spread,
apparently more-adhesive morphology. This result may be
explained by Crk activation of C3G by tyrosine phosphorylation
and C3G-dependent Rap1 activation that promotes cell
adhesion and spreading, but repression of cell migration (Ohba
et al., 2001). The authors also suggest that CrkII-C3G may
function downstream of paxillin, but not p130cas, to suppress
cell migration. CrkII-Y221F fails to induce JNK activation and
cell migration on fibronectin in COS-7 cells (Abassi et al.,
2002). Girardin and Yaniv (Girardin and Yaniv, 2001) reported
that the p130cas/CrkII complex serves as a scaffolding structure
for JNK signaling pathway. With scaffold proteins for mitogen-
activated protein kinase cascades, even though the presence of
an optimal scaffold concentration can increase the signaling
output, if the scaffold concentration is greater than optimal, a
significant decrease in signaling can occur (Levchenko et al.,
Fig. 7. Co-expression of CrkII and PTP1B promotes cell
migration. (A) HT1080 cells in 100 mm dishes were co-
transfected with 1 m g of pHA262pur and 0.5 m g of pcDNA-
CrkII with 0.5 m g or 1.0 m g of pRK-GFP-PTP1B, and
transfectants were selected by puromycin for 36 hours. After
puromycin selection, cells were serum-starved for 12 hours
and then replated on culture dishes coated with 10 m g/ml
fibronectin for 2 hours. The cells were homogenized and
immunoprecipitated with anti-Crk (IP: Crk), anti-p130cas (IP:
p130cas), or anti-paxillin (IP: paxillin) antibodies, and then
immunoblotted with anti-phosphotyrosine (Blot: pTyr), anti-
Crk (Blot: Crk), anti-p130cas (Blot: p130cas), or anti-paxillin
(Blot: paxillin) antibodies. The whole-cell lysates (WCL) were
immunoblotted with anti-PTP1B (Blot: PTP1B) antibody. (B)
HT1080 cells were co-transfected with 0.5 m g of pHA262pur
with 0.3 m g of pcDNA-CrkII-WT or pcDNA-CrkII-Y221F,
and 0.5 m g of pRK-GFP-PTP1B, and transfectants were
selected by puromycin for 36 hours. Cell migration was
measured using 48-well chemotaxis chambers as described in
Materials and Methods. Error bars indicate s.d. for at least
three experiments (*P<0.05 versus controls). 
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2000). A well-studied scaffold for the JNK signaling cascade is
the JNK interacting protein (JIP) family. Indeed, JIP-1 was
originally identified as an inhibitor of the JNK signaling
pathway, whereas the JIP family can function as scaffolding for
the JNK signaling cascade (Dickens et al., 1997; Ito et al.,
1999). Overexpression of the JNK binding domain of JIP-1 can
inhibit JNK activation (Harding et al., 2001). Our results that a
relatively low expression level, but not high expression, of
CrkII-Y221F promoted HT1080 cell migration on fibronectin
is consistent with the ability of CrkII to function as a scaffold
structure binding p130cas in cell migration. Consequently, it
appears that the differing roles of Y221F-CrkII in cell migration
may reflect differing expression and optimal concentration in
different cell types. 
Recent research has revealed that tyrosine phosphorylation
of paxillin reduces cell migration, whereas tyrosine
phosphorylation of p130cas facilitates cell migration (Yano et
al., 2000). In this study, we found that co-expression of CrkII
and PTP1B preferentially protects against dephosphorylation
of p130cas, but not of paxillin, concomitant with promoting cell
migration on fibronectin. The promotion of cell migration by
PTP1B associated with dephosphorylation of paxillin and
CrkII might involve a change in the balance of tyrosine
phosphorylation between p130cas and paxillin. v-Crk has been
implicated in the activation of Rho and phosphatidylinositol 3-
kinase, which are required for focal adhesion formation and
cell migration (Altun-Gultekin et al., 1998; Akagi et al., 2000),
although it is not known whether nononcogenic CrkII also
participates in Rho and phosphatidylinositol 3-kinase
activation. In general, CrkII may act as a molecular switch for
cell migration after binding to p130cas or paxillin and activation
of Rac1 (Klemke et al., 1998).
The data presented here provide the first evidence that
PTP1B directly dephosphorylates CrkII in vitro and in vivo,
with tyrosine residue 221 of CrkII serving as a regulatory
element in binding to tyrosine-phosphorylated proteins and
transducing a signal to induce cell migration on fibronectin. We
conclude that the regulation of CrkII activity by tyrosine
kinases and phosphatases can be an important factor in
regulating cell migration mediated by the FAK/p130cas/CrkII
pathway.
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